AR and prostate cancer: Research is still lacking for small molecules that ortho- or allosterically interact with androgen receptors [125,126], as several other AR-targeted new drugs need to be investigated (such as RNA-based therapies), most of them for prostate cancer, although bladder cancer might also benefit from these [127].